drugset / Trial / NCT00431444

Effects of Zoledronic Acid and Raloxifene on Bone Turnover Markers in Postmenopausal Women With Low Bone Mineral Density

NCT00431444

Phase 4 Completed 110 enrolled Novartis
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will compare the effects of Zoledronic acid and Raloxifene in reducing bone turnover markers in postmenopausal women with low bone mineral density over 6 months.

Timeline

Start
2007-01
Primary completion
2008-07
Completion
2008-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Raloxifene Other / unclassified 60 mg Oral
Comparator Zoledronic acid Other / unclassified 5 mg Intravenous

Indications